Intellia Therapeutics Delivers a Q4 Beat

Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was better than the $1.34 per share loss that analysts had expected, and revenue of $12.9 million, significantly outpacing the $7 million estimate. Source: Analysts' estimates for the quarter provided by FactSet.Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin amyloidosis and hereditary angioedema, respectively. Its therapies utilize Intellia's proprietary lipid nanoparticle (LNP) delivery system, potentially offering functional cures for genetic conditions via single-dose treatments. Strategic collaborations and a robust patent portfolio bolster its competitive edge in the gene-editing market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool